NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression an

Go back to NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression an
(NASDAQ: NRXP) Delayed: 3.95 -0.02 (0.5%)
Previous Close $3.97    52 Week High
Open $3.99    52 Week Low
Day High $4.17    P/E N/A 
Day Low $3.94    EPS
Volume 263,935